TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days

Product details: Injectable (Insulin Syringes) 10MLVial (10 shots per vial) Order comes with 2 10ML Vials OR 1 20ML Vial MICC (Methionine/Inositol/Choline/Cyanocobalamin): 25MG/50MG/50MG/330MCG/ML All Wellness Medicines and Compounded Pharmacy Products require a Quick & Easy Medical Evaluation to Ensure the Medication is Appropriate for you
Liposomal glutathione can provide immediate cellular benefits, though it typically comes at a higher cost
The roles and intervention timing of calcium ion channel antagonists, hepcidin activators, antioxidants, and gene therapy are currently under further investigation